Details for New Drug Application (NDA): 040015
✉ Email this page to a colleague
NDA 040015 describes NEOSAR, which is a drug marketed by Bedford and Teva Parenteral and is included in two NDAs. Additional details are available on the NEOSAR profile page.
The generic ingredient in NEOSAR is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
The generic ingredient in NEOSAR is cyclophosphamide. There are nineteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.
Summary for 040015
| Tradename: | NEOSAR |
| Applicant: | Teva Parenteral |
| Ingredient: | cyclophosphamide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 040015
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/VIAL | ||||
| Approval Date: | Apr 29, 1993 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 200MG/VIAL | ||||
| Approval Date: | Apr 29, 1993 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/VIAL | ||||
| Approval Date: | Apr 29, 1993 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
